|
Valoración de DCF de Immix BioPharma, Inc. (IMMX)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Immix Biopharma, Inc. (IMMX) Bundle
¿Busca evaluar el valor intrínseco de Immix BioPharma, Inc.? Nuestra calculadora DCF (IMMX) integra datos del mundo real con extensas características de personalización, lo que le permite refinar sus pronósticos y mejorar sus estrategias de inversión.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | -89.5 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | -100 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -.8 | -.5 | -1.3 | -8.2 | -16.1 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 9.18 | 100 | 81.84 | 81.84 | 81.84 | 81.84 | 81.84 |
Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | -0.00238502 | 100 | 80 | 80 | 80 | 80 | 80 |
EBIT | -.8 | -.5 | -1.4 | -8.2 | -16.1 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 9.18 | 100 | 81.84 | 81.84 | 81.84 | 81.84 | 81.84 |
Total Cash | .7 | .4 | 17.6 | 13.4 | 17.5 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | .1 | .0 | .3 | 1.2 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | -0.28565 | 100 | 79.94 | 79.94 | 79.94 | 79.94 | 79.94 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | .2 | .3 | .1 | .1 | 1.4 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | -0.15983 | 100 | 79.97 | 79.97 | 79.97 | 79.97 | 79.97 |
Capital Expenditure | .0 | .0 | .0 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 0 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 | 0.91886 |
EBITAT | -.9 | -.5 | -1.4 | -8.2 | -16.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -.8 | -.4 | -1.4 | -8.5 | -15.7 | -.3 | .0 | .0 | .0 | .0 |
WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
PV UFCF | ||||||||||
SUM PV UFCF | -.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | 0 | |||||||||
Net Debt | -18 | |||||||||
Equity Value | 17 | |||||||||
Diluted Shares Outstanding, MM | 17 | |||||||||
Equity Value Per Share | 1.00 |
What You Will Get
- Real Immix Biopharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Immix Biopharma, Inc. (IMMX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Immix Biopharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to Immix Biopharma, Inc. (IMMX).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for your financial assessments.
Key Features
- Comprehensive IMMX Data: Pre-filled with Immix Biopharma's historical financials and future growth projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investment plans.
- Adaptive Valuation Framework: Instant updates to Net Present Value (NPV) and intrinsic value based on your tailored inputs.
- Scenario Analysis: Develop various forecasting scenarios to explore different valuation possibilities.
- User-Centric Interface: Intuitive, organized, and suitable for both industry veterans and newcomers.
How It Works
- Download: Get the comprehensive Excel file featuring Immix Biopharma, Inc.'s (IMMX) financial data.
- Customize: Tailor your forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and evaluate outcomes immediately.
- Make Decisions: Leverage the valuation results to inform your investment strategy.
Why Choose This Calculator for Immix Biopharma, Inc. (IMMX)?
- Designed for Industry Experts: A sophisticated tool tailored for biopharma analysts, investors, and researchers.
- Comprehensive Data: Immix Biopharma’s historical and projected financials preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically calculates intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the calculation process.
Who Should Use This Product?
- Investors: Accurately assess Immix Biopharma’s fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immix Biopharma, Inc. (IMMX).
- Consultants: Efficiently customize the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biopharma companies.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the life sciences field.
What the Immix Biopharma, Inc. (IMMX) Template Contains
- Comprehensive DCF Model: Editable template featuring in-depth valuation calculations tailored for biopharmaceutical analysis.
- Real-World Data: Immix Biopharma’s historical and projected financials preloaded for thorough examination.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns to provide deeper insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to the biopharma sector.
- Dashboard with Visual Outputs: Interactive charts and tables for clear, actionable insights.